1
|
New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. Toxins (Basel) 2021; 13:toxins13120834. [PMID: 34941672 PMCID: PMC8705745 DOI: 10.3390/toxins13120834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 11/09/2021] [Accepted: 11/16/2021] [Indexed: 11/16/2022] Open
Abstract
Botulinum neurotoxins (BoNTs) are notorious toxins and powerful agents and can be lethal, causing botulism, but they are also widely used as therapeutics, particularly to treat neuromuscular disorders. As of today, the commercial BoNT treatments available are from native A or B serotypes. Serotype F has shown efficacy in a clinical trial but has scarcely been used, most likely due to its medium duration of effect. Previously, the uniqueness of the light chain of the F7 subtype was identified and reported, showing an extended interaction with its substrates, VAMPs 1, 2 and 3, and a superior catalytic activity compared to other BoNT/F subtypes. In order to more extensively study the properties of this neurotoxin, we engineered a modified F7 chimera, mrBoNT/F7-1, in which all the regions of the neurotoxin were identical to BoNT/F7 except the activation loop, which was the activation loop from BoNT/F1. Use of the activation loop from BoNT/F1 allowed easier post-translational proteolytic activation of the recombinant protein without otherwise affecting its properties. mrBoNT/F7-1 was expressed, purified and then tested in a suite of in vitro and in vivo assays. mrBoNT/F7-1 was active and showed enhanced potency in comparison to both native and recombinant BoNT/F1. Additionally, the safety profile remained comparable to BoNT/F1 despite the increased potency. This new modified recombinant toxin F7 could be further exploited to develop unique therapeutics to address unmet medical needs.
Collapse
|
2
|
Yadav SK, Singh M, Sarkaraisamy P. Expression and purification of catalytic domain of botulinum neurotoxin serotype ‘F’: immunological characterization and its application in detection. FOOD BIOTECHNOL 2020. [DOI: 10.1080/08905436.2020.1740731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Shiv Kumar Yadav
- BDTE Division, Defence Research & Development Establishment, Gwalior, India
| | - Monika Singh
- BDTE Division, Defence Research & Development Establishment, Gwalior, India
| | | |
Collapse
|
3
|
Sikorra S, Skiba M, Dorner MB, Weisemann J, Weil M, Valdezate S, Davletov B, Rummel A, Dorner BG, Binz T. Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q 58⁻K 59 Peptide Bond Exhibit Unique Catalytic Properties and Substrate Specificities. Toxins (Basel) 2018; 10:toxins10080311. [PMID: 30071628 PMCID: PMC6116196 DOI: 10.3390/toxins10080311] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 07/23/2018] [Accepted: 07/30/2018] [Indexed: 11/16/2022] Open
Abstract
In the recent past, about 40 botulinum neurotoxin (BoNT) subtypes belonging to serotypes A, B, E, and F pathogenic to humans were identified among hundreds of independent isolates. BoNTs are the etiological factors of botulism and represent potential bioweapons; however, they are also recognized pharmaceuticals for the efficient counteraction of hyperactive nerve terminals in a variety of human diseases. The detailed biochemical characterization of subtypes as the basis for development of suitable countermeasures and possible novel therapeutic applications is lagging behind the increase in new subtypes. Here, we report the primary structure of a ninth subtype of BoNT/F. Its amino-acid sequence diverges by at least 8.4% at the holotoxin and 13.4% at the enzymatic domain level from all other known BoNT/F subtypes. We found that BoNT/F9 shares the scissile Q58/K59 bond in its substrate vesicle associated membrane protein 2 with the prototype BoNT/F1. Comparative biochemical analyses of four BoNT/F enzymatic domains showed that the catalytic efficiencies decrease in the order F1 > F7 > F9 > F6, and vary by up to a factor of eight. KM values increase in the order F1 > F9 > F6 ≈ F7, whereas kcat decreases in the order F7 > F1 > F9 > F6. Comparative substrate scanning mutagenesis studies revealed a unique pattern of crucial substrate residues for each subtype. Based upon structural coordinates of F1 bound to an inhibitor polypeptide, the mutational analyses suggest different substrate interactions in the substrate binding channel of each subtype.
Collapse
Affiliation(s)
- Stefan Sikorra
- Institute of Cell Biochemistry, OE 4310, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
| | - Martin Skiba
- Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany.
| | - Martin B Dorner
- Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany.
| | - Jasmin Weisemann
- Institute of Toxicology, OE 5340, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
| | - Mirjam Weil
- Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany.
| | - Sylvia Valdezate
- Reference and Research Laboratory for Taxonomy, Spanish National Centre of Microbiology, Institute of Health Carlos III, 28220 Madrid, Spain.
| | - Bazbek Davletov
- Department of Biomedical Science, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.
| | - Andreas Rummel
- Institute of Toxicology, OE 5340, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
| | - Brigitte G Dorner
- Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany.
| | - Thomas Binz
- Institute of Cell Biochemistry, OE 4310, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
| |
Collapse
|